Wire
FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List
FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List
$LLY$NVO
Eli Lilly and Company
$LLYNYSEHealthcare
147 stories mentioning Eli Lilly and CompanyUpdated 5h ago
Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.
Sectors
Sector Update: Health Care Stocks Rise Premarket Thursday
Health care stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1% higher and the iShares Biotechnology ETF (IBB) up 0.6%.Eli Lilly (LLY) shares were up more than 5% after the company reported higher Q1 non-GAAP earnings and revenue, and raised its 2026 outlook.Merck (MRK) stock was down more than 1% after the company said it swung to a Q1 adjusted loss.Alnylam Pharmaceuticals (ALNY) shares were up more than 2% after the company posted higher Q1 adjusted net income and revenue.
$ALNY$IBB$LLY$MRK$XLV
Sectors
Sector Update: Health Care
Health care stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.9% higher and the iShares Biotechnology ETF (IBB) up 0.5%.Eli Lilly (LLY) shares were up 6% after the company reported higher Q1 non-GAAP earnings and revenue, and raised its 2026 outlook.
$LLY
US Markets
Eli Lilly Raises 2026 Outlook Following First-Quarter Beat
Eli Lilly (LLY) raised its full-year outlook on Thursday while the drugmaker reported first-quarter results above market estimates, as sales of its Mounjaro diabetes treatment more than doubled year over year.The drugmaker now expects adjusted earnings to be in a range of $35.50 to $37 per share for 2026, up from its previous projections of $33.50 to $35. Revenue is pegged at $82 billion to $85 billion, compared with the prior guidance of $80 billion to $83 billion.The current consensus on FactSet is for non-GAAP EPS of $34.51 and sales of $82.07 billion for the year."2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion," Chief Executive David Ricks said in a statement. "We also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly's future growth through four acquisitions."For the quarter ended March, Eli Lilly's adjusted EPS soared to $8.55 from $3.34 the year before, surpassing the Street's view of $6.97. Revenue jumped to $19.8 billion from $12.73 billion, well ahead of the average analyst estimate of $17.82 billion.The stock climbed 6.2% in the most recent premarket activity.Sales in the US advanced 43% to $12.1 billion, boosted by a 49% increase in volume, partially offset by lower prices, driven by weight-loss drug Zepbound and plaque psoriasis treatment Taltz, according to the firm. Revenue from non-US markets surged 81% to $7.7 billion amid volume growth of 95%.Revenue from Mounjaro spiked to $8.66 billion from $3.84 billion last year, amid gains in the US and international markets, boosted by robust demand and volume growth, respectively. Zepbound sales climbed to $4.16 billion from $2.31 billion, buoyed by higher demand.Eli Lilly said a recent milestone for the company was the US Food and Drug Administration's approval of its Foundayo, or orforglipron, drug for adults with obesity, or overweight with weight-related medical problems. In an emailed client note, Truist Securities said it believes the new product is likely to expand the market and not "cannibalize" it.
$LLY
Asia Markets
Big Tech Earnings, Fed Rate Decision Lift US Equity Futures Pre-Bell
US equity futures were higher pre-bell Thursday as traders absorbed the latest round of financial results, including those of big tech, amid the Federal Open Market Committee maintaining its target rate.Dow Jones Industrial Average futures were 0.6% higher, S&P 500 futures were up 0.5%, and Nasdaq futures were 0.7% higher.Alphabet (GOOG, GOOGL), Amazon (AMZN), and Meta Platforms (META) all reported higher earnings and revenue for Q1, while Microsoft (MSFT) posted an increase in fiscal Q3 adjusted earnings and revenue. Apple (AAPL) is expected to publish its fiscal Q2 financial results after-market.The Federal Open Market Committee maintained the target range for its federal funds rate at 3.50% to 3.75%, as expected, but the level of dissent was reportedly the highest since 1992, with four officials dissenting.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 0.7% at $109.72 per barrel and US West Texas Intermediate crude 1.2% lower at $106.61 per barrel.In other world markets, Japan's Nikkei closed 1.1% lower, Hong Kong's Hang Seng ended 1.3% lower, and China's Shanghai Composite finished 0.1% higher. Meanwhile, the UK's FTSE 100 was up 1.4%, and Germany's DAX index was 0.9% higher in Europe's early afternoon session.The March core personal consumption expenditures price index, the Federal Reserve's preferred inflation gauge, released at 8:30 am ET, gained 0.3%, lower than 0.4% in the prior month and meeting estimates compiled by Bloomberg.Initial jobless claims declined to 189,000 in the week ended April 25 from an upwardly revised 215,000 level in the previous week, compared with expectations for a decrease to 212,000. Q1 GDP growth was recorded at a 2.0% annual rate, compared with expectations for 2.3%.In equities, Alphabet and Amazon shares rose 7.3% and 3.4%, respectively, after the companies reported their Q1 financial results. Eli Lilly (LLY) stock was up 6.1% after the company posted Q1 non-GAAP earnings and revenue that surpassed analysts' consensus and boosted its full-year 2026 guidance.On the losing side, Meta Platforms shares were 8.4% lower, a day after the company said it raised its 2026 capital expenses outlook and reported a decline in its daily active users on a quarter-over-quarter basis. Stellantis (STLA) stock was down 2.6% after the company reported Q1 net revenue that fell short of analysts' estimates. Microsoft shares were down 0.9% despite the company posting a fiscal Q3 adjusted earnings and revenue beat.
Dow JonesNasdaq CompositeS&P 500$AAPL$AMZN$GOOG$GOOGL$LLY$META$MSFT$STLA
Commodities
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Big Tech Earnings, Economic Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.5% in Thursday's premarket activity, amid optimistic big tech earnings reports and a deluge of economic data.US stock futures were also higher, with S&P 500 Index futures up 0.4%, Dow Jones Industrial Average futures advancing 0.6%, and Nasdaq futures gaining 0.5% before the start of regular trading.Reports releasing at 8:30 am ET include the Q1 gross domestic product (GDP) from Washington, the personal consumption expenditures (PCE)-core inflation report for March, the weekly jobless claims bulletin, and the Q1 Employment Cost Index.The April Chicago PMI posts at 9:45 am, followed by the February leading indicators report at 10 am, and the weekly natural gas stocks at 10:30 am ET.In premarket action, bitcoin was down by 0.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.7% higher, Ether ETF (EETH) advanced 1.4%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated by 0.5%. Direxion Daily Financial Bull 3X Shares (FAS) was down 1.5%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was up 1.9%.Willis Towers Watson (WTW) shares were down more than 9% pre-bell after the company reported higher Q1 adjusted earnings and revenue.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 1.2%, the Vanguard Health Care Index Fund (VHT) was 1.1% higher, while the iShares US Healthcare ETF (IYH) was up 0.7%. The iShares Biotechnology ETF (IBB) gained 0.2%.Eli Lilly (LLY) stock was up more than 7% premarket after the company reported higher Q1 non-GAAP earnings and revenue.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained by 0.4%, and the iShares US Technology ETF (IYW) was 1% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.7%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) rose 2%, while the iShares Semiconductor ETF (SOXX) advanced by 1.3%.Alphabet's (GOOG, GOOGL) shares were up 7% in Thursday's premarket activity after the tech giant reported overnight Q1 earnings and sales above market expectations.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.5%, while the Vanguard Industrials Index Fund (VIS) was up 1.6% and the iShares US Industrials ETF (IYJ) gained 0.4%.Caterpillar (CAT) stock was up more than 5% before the opening bell after the company reported higher Q1 adjusted profit and revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.3%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was 0.2% lower, and the iShares US Consumer Staples ETF (IYK) retreated 0.1%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) was up 0.6%. The VanEck Retail ETF (RTH) gained 0.03%, while the State Street SPDR S&P Retail ETF (XRT) declined by 0.6%.Unilever (UL) shares were up more than 2% pre-bell after the company said its Q1 underlying sales grew by 3.8%.EnergyThe iShares US Energy ETF (IYE) was down 0.9%, while the State Street Energy Select Sector SPDR ETF (XLE) declined by 1.1%.ConocoPhillips (COP) stock was down more than 2% before the opening bell after the company reported lower Q1 adjusted earnings and revenue.CommoditiesFront-month US West Texas Intermediate crude oil fell by 2.3% to $104.44 per barrel on the New York Mercantile Exchange. Natural gas retreated by 1.4% to $2.61 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 2.6%, while the United States Natural Gas Fund (UNG) was 1.5% lower.Gold futures for May were up by 1.8% to $4,641.80 an ounce on the Comex. Silver futures rose by 2.6% to $73.96 an ounce. SPDR Gold Shares (GLD) was 1.9% higher, and the iShares Silver Trust (SLV) gained by 2.7%.
Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CAT$COP$EEM$EETH$EXI$FAS$FAZ$GLD$GOOG$GOOGL$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LLY$PMR$QQQ$RTH$SLV$SOXX$SPY$UL$UNG$USO$VDC$VHT$VIS$WTW$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Research
Research Alert: Lly Q1 Tops Estimates: Glp-1 Sales Fuel Record Growth And Strategic Expansion
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LLY delivered exceptional Q1 results with non-GAAP EPS of $8.55 (+156% Y/Y), $1.56 above consensus, and revenue of $19.8B (+56%), $2M above estimates. The GLP-1 franchise drove performance with combined Mounjaro and Zepbound sales reaching ~$12.8B, representing 65% of total revenue, with Mounjaro achieving $8.7B (+125%) and Zepbound $4.2B (+80%). We view the continued GLP-1 momentum, strong international expansion including China NRDL inclusion, and FDA approval of the Foundayo oral pill as key catalysts supporting our investment thesis. Management raised 2026 guidance to $82B-$85B revenue and $35.50-$37.00 non-GAAP EPS, demonstrating confidence in sustained solid growth. The company accelerated strategic capital deployment with four proposed acquisitions in Q1, including Orna Therapeutics and Kelonia Therapeutics, while increasing R&D investment 28% to $3.5B, reflecting commitment to pipeline diversification across oncology and next-generation therapeutics, in our view.
$LLY
US Markets
Stocks Mostly Up Pre-Bell as Traders Digest Big Tech Earnings, Await Key Inflation Report
US equity markets were mostly pointing higher before the opening bell Thursday as investors digest the latest financial results from some of the biggest technology companies and await a key inflation report.The S&P 500 rose 0.1% and the Nasdaq added 0.2% in premarket activity, while the Dow Jones Industrial Average declined 0.2%. The indexes finished the previous trading session mixed.Shares of Meta Platforms (META) fell 8.8% pre-bell after the Facebook parent lifted its full-year capital expenditure guidance mainly due to higher component pricing, even though it reported stronger-than-expected first-quarter results. Microsoft (MSFT) decreased 1.8% as the tech giant said its capital expenditures will be about $190 billion in 2026, while its fiscal third-quarter results topped market estimates."It's crystal clear to us that the (artificial intelligence) revolution is accelerating at a warp speed pace with 2026 being an inflection point year for AI with hyperscalers now investing over $700 billion in (capital expenditures) in (2026) to capitalize on the opportunities in the space," Wedbush Securities said in a Thursday client note.Alphabet's (GOOG, GOOGL) class A and C shares climbed more than 6% each amid upbeat first-quarter results. Amazon (AMZN) inclined 2.5% as the e-commerce giant issued a strong second-quarter revenue outlook.iPhone maker Apple (AAPL) is scheduled to release its quarterly earnings after the markets close. Eli Lilly (LLY), Mastercard (MA), Caterpillar (CAT), Merck (MRK), Royal Caribbean Cruises (RCL) and Hershey (HSY) are slated to announce their results before the bell, among others.The personal income and outlays report for March is due to be released at 8:30 am ET. The report includes the personal consumption expenditure core price index, the Federal Reserve's preferred inflation metric.The central bank's Federal Open Market Committee left its benchmark interest rate unchanged on Wednesday as policymakers saw the Middle East conflict fueling uncertainty around the US economic outlook. In a post-meeting press conference, Jerome Powell said he will stay on as a Fed governor for an indefinite period after his term as Fed chief expires on May 15.The US Senate Banking Committee on Wednesday voted to advance Kevin Warsh's nomination as Fed chair to the Republican-controlled Senate.Treasury yields were down in premarket action, with the two-year rate retreating 3.2 basis points to 3.9% and the 10-year rate off 1.8 basis points to 4.4%.President Donald Trump is expected to receive a briefing on fresh potential military options against Iran on Thursday, Axios reported, citing two sources with knowledge. Trump recently told the news outlet that he will maintain the US naval blockade of Iranian ports until Tehran agrees to a nuclear deal.West Texas Intermediate crude oil slipped 0.2% to $106.62 a barrel before the open, while Brent decreased 1.6% to $116.20.Thursday's economic calendar also has the initial estimate report for the first-quarter gross domestic product at 8:30 am, along with the weekly jobless claims bulletin. The Chicago purchasing managers' index for April posts at 9:45 am.Gold rose 1.8% to $4,642 per troy ounce, while bitcoin moved 0.7% higher to $75,974.
Dow JonesNasdaq CompositeS&P 500$AAPL$AMZN$CAT$GOOG$GOOGL$HSY$LLY$MA$META$MRK$MSFT$RCL
Sectors
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks edged up late Tuesday afternoon, with the NYSE Health Care Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.The iShares Biotechnology ETF (IBB) declined 0.6%.In sector news, the US Food and Drug Administration plans to pilot an approach this summer that will use AI to accelerate clinical trials of new medicines by automating data collection and submission, The Wall Street Journal reported Tuesday, citing an interview with Jeremy Walsh, the FDA's chief AI officer.In corporate news, Axogen (AXGN) shares jumped past 6% after it reported Tuesday a swing to Q1 adjusted EPS from a a loss a year earlier following a surge in revenue.Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment. Pfizer shares were down 1.7%.Eli Lilly (LLY) has entered into a strategic partnership with Profluent to develop AI-designed recombinases for genetic medicines, Profluent said Tuesday. Lilly shares rose 0.6%.Novartis (NVS) reported Q1 core earnings Tuesday of $1.99 per share, down from $2.28 a year earlier. Analysts polled by FactSet expected $2.19. Net sales for the quarter ended March 31 were $13.11 billion, down from $13.23 billion a year earlier. For 2026, the company said it continues to expect a low-single-digit core operating income decline. Novartis shares were up 0.3%.
$AXGN$LLY$NVS$PFE
Sectors
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon
Health care stocks edged up Tuesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.2%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment. Pfizer shares were down 0.8%.Eli Lilly (LLY) has entered into a strategic partnership with Profluent to develop AI-designed recombinases for genetic medicines, Profluent said Tuesday. Lilly shares decreased 0.2%.Novartis (NVS) reported Q1 core earnings Tuesday of $1.99 per share, down from $2.28 a year earlier. Analysts polled by FactSet expected $2.19. Net sales for the quarter ended March 31 were $13.11 billion, down from $13.23 billion a year earlier. For 2026, the company said it continues to expect a low-single-digit core operating income decline. Novartis shares were fractionally lower.
$LLY$NVS$PFE
Sectors
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks fell late Monday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) losing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Eli Lilly (LLY) agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of clinical and regulatory milestones. Lilly shares fell 1.6%.HCA Healthcare (HCA) may face pressure through at least H1 as investors rotate toward managed care, although better trends in March and in-line exchange dynamics support the longer-term outlook, RBC Capital Markets said. HCA Healthcare shares rose 3.2%.Organon (OGN) shares jumped 17% after the company agreed to be acquired by India's Sun Pharmaceutical Industries for $14 a share in cash, valuing the company at $11.75 billion.Moderna (MRNA) is facing a patent infringement lawsuit from CureVac, which alleged that Moderna's COVID-19 vaccine Spikevax used its proprietary mRNA technology without authorization, Reuters reported Saturday. Moderna shares fell 4.7%.
$HCA$LLY$MRNA$OGN
Wire
S&P 500 Companies' Quarterly Profit Growth Eases, But Remains Well Above Expectations, Oppenheimer Says
S&P 500 companies' quarterly earnings growth decelerated compared with figures from a week ago, but remained well ahead of expectations, Oppenheimer Asset Management's data showed Monday.Some 28% of companies in the benchmark equity index have reported results in the latest cycle, with earnings up about 25% from a year earlier and revenue growing 10%. Last week's report by the brokerage showed profit growth of 32% and sales increase of 13%, based on financials reported by 9% of the index constituents.Ahead of the reporting season, FactSet put expected earnings growth at 12.6% from a year earlier, according to Oppenheimer."The quarter appears to be off to a strong start," Oppenheimer Asset Management Chief Investment Strategist John Stoltzfus said, noting that earnings growth reported by 79% of the firms that have released their quarterly results exceeded analyst estimates.Among sectors, materials and technology outperformed in terms of earnings, with profit roughly doubling year over year. Tech led the chart for revenue growth, with a nearly 30% increase, followed by real estate's 14% jump.This week, a busier earnings calendar has 179 S&P companies releasing their quarterly financials, according to Oppenheimer. Among the big-cap companies reporting this week are five of the so-called Magnificent 7 stocks; Alphabet (GOOG, GOOGL), Apple (AAPL), Microsoft (MSFT), Amazon (AMZN) and Meta Platforms (META).Visa (V), Coca-Cola (KO), T-Mobile US (TMUS), and Eli Lilly (LLY) also report this week.On Friday, the S&P 500 and the Nasdaq Composite hit all-time peaks as tech stocks rallied, ahead of a second round of US-Iran peace talks. The two sides, however, didn't have direct negotiations in Pakistan over the weekend."Resolution to the conflict in our view persists as a potential negative overhang to market performance on a day-to-day basis tied to news flows from the front, developments in negotiations taking place and supply chain disruptions that carry inflation risks," Stoltzfus said. "That said, stocks are showing thus far an appreciation for fundamentals that matter to revenue and profit growth."Price: $349.73, Change: $+7.41, Percent Change: +2.16%
$AAPL$AMZN$GOOG$GOOL$KO$LLY$META$MSFT$TMUS$V
Sectors
Sector Update: Health Care Stocks Softer in Afternoon Trading
Health care stocks were lower Monday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.2%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Eli Lilly (LLY) said Monday it has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of clinical and regulatory milestones, the company said. Lilly shares were down 0.5%.Organon (OGN) shares jumped 17% after the company agreed to be acquired by India's Sun Pharmaceutical Industries $14 a share in cash, valuing the company at $11.75 billion.Moderna (MRNA) is facing a patent infringement lawsuit from CureVac, which alleged that Moderna's COVID-19 vaccine Spikevax used its proprietary mRNA technology without authorization, Reuters reported Saturday. Moderna shares were falling 3.3%.Catalyst Pharmaceuticals (CPRX) is being considered as a potential acquisition by Italy's Angelini Pharma, Bloomberg reported. Catalyst shares rose past 6%.
$CPRX$LLY$MRNA$OGN
Wire
Top Midday Stories: Microsoft, OpenAI Amend Agreement; Qualcomm Reportedly Collaborating With OpenAI on Smartphone AI Chip
All three major US stock indexes were down in late-morning trading Monday, as investors parse ongoing developments in peace talks between the US and Iran.Iran has offered to reopen the Strait of Hormuz in exchange for an end to the US' blockade of the country and an end to the war, media outlets reported Monday, citing officials.In company news, Microsoft (MSFT) and OpenAI said Monday they have amended their agreement so that Microsoft will no longer pay a revenue share to OpenAI, and its license will now be non-exclusive. Microsoft will remain OpenAI's primary cloud partner, and its Azure will receive the first shipments of OpenAI products, unless Microsoft cannot and chooses not to support the necessary capabilities, the companies said. Separately, industry checks indicate that OpenAI is working with Qualcomm (QCOM) and MediaTek to develop smartphone processors, a TF International Securities analyst said. Microsoft shares were down 0.7% around midday, while Qualcomm shares were down 0.2%.ARC Resources said Monday it has entered into a definitive agreement to be acquired by Shell (SHEL) in a cash-and-share deal valued at about 22 billion Canadian dollars ($16.17 billion). Under the terms of the deal, ARC shareholders will receive 0.40247 of a Shell share and CA$8.20 in cash consideration in exchange for each ARC share they own, representing a total consideration of CA$32.80 per ARC share. The deal is expected to close in H2, ARC said. Shell shares were down 1.3%.Meta Platforms' (META) $2 billion acquisition of AI startup Manus was blocked by China's National Development and Reform Commission, media outlets reported Monday, citing the Chinese regulator. Meta shares were down 0.1%.Eli Lilly (LLY) said Monday it has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of certain clinical and regulatory milestones, the company said. Eli Lilly shares were down 0.5%.Verizon Communications (VZ) reported Q1 adjusted earnings Monday of $1.28 per diluted share, up from $1.19 a year earlier and above the FactSet consensus analyst estimate of $1.21. First-quarter operating revenue was $34.44 billion, up from $33.49 billion a year ago but below the FactSet consensus of $34.82 billion. For 2026, the company said it expects adjusted EPS of $4.95 to $4.99, above the FactSet consensus of $4.90. Verizon shares were up 3.6%.Price: $422.11, Change: $-2.49, Percent Change: -0.59%
$LLY$META$MSFT$QCOM$SHEL$VZ
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Eli Lilly And Company
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of LLY are down 3.60% today after reports of weaker-than-expected sales of the GLP-1 oral pill Foundayo in its first two weeks of launch in April. We think the news does not change our thesis, as we expected Foundayo to make a meaningful contribution to LLY's results starting in 2027. While we acknowledge that this initial data fell short of expectations, we think it is too early to draw a conclusion and Foundayo sales may catch up in the coming months. On Tuesday, Amazon launched a comprehensive weight management program that integrates primary care, pharmacy services, and virtual care for GLP-1 treatment, which should increase Foundayo's accessibility, in our view. This allows oral GLP-1s (Foundayo and Wegovy pill) at $25/month with insurance and $149/month cash-pay. Based on CDC data, around 40% of the U.S. adult population is obese. Thus, there is still a vast addressable market and Foundayo, with its ease to use (once-daily) and tolerability, is a strong product, in our view.
$LLY
Wire
Guggenheim Adjusts Price Target on Eli Lilly to $1,183 From $1,163, Maintains Buy Rating
Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,240.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $882.98, Change: $-36.93, Percent Change: -4.01%
$LLY
Sectors
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Tvardi Therapeutics (TVRD) shares fell 4.1% after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.6%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 42%, and GH Research jumped 17%.Nektar Therapeutics (NKTR) shares climbed 18% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.
$CMPS$GHRS$LLY$NKTR$TVRD
Research
Research Alert: CFRA Keeps Buy Rating On Shares Of Eli Lilly After Kelonia Deal Announcement
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target price at $1,225, 29.0x our 2027 EPS view, below LLY's five-year historical forward P/E average. We retain our 2026 EPS at $34.71 and lift our 2027 EPS to $42.22 from $42.12. LLY announced today it is acquiring Kelonia Therapeutics for up to $7B to access its iGPS platform, enabling in vivo CAR-T therapy that reprograms T-cells to fight cancer inside the body via a single IV infusion. Kelonia's lead candidate KLN-1010 targets BCMA in multiple myeloma, the second most frequent U.S. blood cancer. Similarly, LLY announced the acquisition of Orna Therapeutics for up to $1B in February to access its circular RNA platform, which offers longer-lasting protein expression, reduced immunogenicity, and larger genetic payloads versus traditional mRNA. These acquisitions reflect LLY's strategy of deploying GLP-1 cash flow to build a diversified pipeline in oncology, autoimmune diseases and next-generation therapeutic modalities, in our view.
$LLY
Sectors
Sector Update: Health Care Stocks Softer Monday Afternoon
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.5%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.1%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 47%, and GH Research jumped 15%.Nektar Therapeutics (NKTR) shares climbed 22% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.
$CMPS$GHRS$LLY$NKTR
Sectors
Sector Update: Health Care
Health care stocks declined Monday afternoon, with the NYSE Health Care Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) was down 0.3%.In corporate news, Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares eased 0.1%.
$LLY
Showing 121-140 of 147
